Samuel A Wells1, Sylvia L Asa2, Henning Dralle3, Rossella Elisei4, Douglas B Evans5, Robert F Gagel6, Nancy Lee7, Andreas Machens3, Jeffrey F Moley8, Furio Pacini9, Friedhelm Raue10, Karin Frank-Raue10, Bruce Robinson11, M Sara Rosenthal12, Massimo Santoro13, Martin Schlumberger14, Manisha Shah15, Steven G Waguespack6. 1. 1Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. 2Department of Pathology, University Health Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 3. 3Department of General, Visceral, and Vascular Surgery, University Hospital, University of Halle-Wittenberg, Halle/Saale, Germany. 4. 4Department of Endocrinology, University of Pisa, Pisa, Italy. 5. 5Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. 6. 6Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. 7Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 8. 8Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. 9. 9Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Siena, Italy. 10. 10Endocrine Practice, Moleculargenetic Laboratory, Medical Faculty, University of Heidelberg, Heidelberg, Germany. 11. 11University of Sydney School of Medicine, Sydney, New South Wales, Australia. 12. 12Departments of Internal Medicine, Pediatrics and Behavioral Science, University of Kentucky, Lexington, Kentucky. 13. 13Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universita' di Napoli "Federico II," Napoli, Italy. 14. 14Institut Gustave Roussy, Service de Medecine Nucleaire, Université of Paris-Sud, Villejuif, France. 15. 15Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Abstract
INTRODUCTION: The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association. METHODS: The Task Force identified relevant articles using a systematic PubMed search, supplemented with additional published materials, and then created evidence-based recommendations, which were set in categories using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research and Quality. The original guidelines provided abundant source material and an excellent organizational structure that served as the basis for the current revised document. RESULTS: The revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic medullary thyroid carcinoma (MTC) and hereditary MTC. CONCLUSIONS: The Task Force developed 67 evidence-based recommendations to assist clinicians in the care of patients with MTC. The Task Force considers the recommendations to represent current, rational, and optimal medical practice.
INTRODUCTION: The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association. METHODS: The Task Force identified relevant articles using a systematic PubMed search, supplemented with additional published materials, and then created evidence-based recommendations, which were set in categories using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research and Quality. The original guidelines provided abundant source material and an excellent organizational structure that served as the basis for the current revised document. RESULTS: The revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic medullary thyroid carcinoma (MTC) and hereditary MTC. CONCLUSIONS: The Task Force developed 67 evidence-based recommendations to assist clinicians in the care of patients with MTC. The Task Force considers the recommendations to represent current, rational, and optimal medical practice.
Authors: Adriana B Nunes; Marilza C L Ezabella; Alexandre C Pereira; José E Krieger; Sergio P A Toledo Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: Curtis J Wray; Thereasa A Rich; Steven G Waguespack; Jeffrey E Lee; Nancy D Perrier; Douglas B Evans Journal: Ann Surg Oncol Date: 2007-10-26 Impact factor: 5.344
Authors: Jian Yu Xu; William A Murphy; Denái R Milton; Camilo Jimenez; Sarika N Rao; Mouhammed Amir Habra; Steven G Waguespack; Ramona Dadu; Robert F Gagel; Anita K Ying; Maria E Cabanillas; Steven P Weitzman; Naifa L Busaidy; Rena V Sellin; Elizabeth Grubbs; Steven I Sherman; Mimi I Hu Journal: J Clin Endocrinol Metab Date: 2016-09-23 Impact factor: 5.958
Authors: Philip M Spanheimer; Ian Ganly; Joanne Chou; Marinela Capanu; Ronald A Ghossein; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Brian R Untch Journal: Ann Surg Oncol Date: 2019-09-23 Impact factor: 5.344